Details of the Drug Combination

General Information of Drug Combination (ID: DCPML0E)

Drug Combination Name
Ridaforolimus SCH-900776
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs Ridaforolimus   DMLHEU7 SCH-900776   DM67EMK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: HCT116
Zero Interaction Potency (ZIP) Score: 1.17
Bliss Independence Score: 4.74
Loewe Additivity Score: 1.2
LHighest Single Agent (HSA) Score: 6.16

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Ridaforolimus
Disease Entry ICD 11 Status REF
Sarcoma 2A60-2C35 Phase 3 [2]
Ridaforolimus Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Serine/threonine-protein kinase mTOR (mTOR) TTCJG29 MTOR_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Indication(s) of SCH-900776
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
SCH-900776 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Checkpoint kinase-1 (CHK1) TTTU902 CHK1_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Colon carcinoma DCWZ7WW RKO Investigative [6]
Rectal adenocarcinoma DCESKXL SW837 Investigative [6]
Adenocarcinoma DCK3IF8 COLO320DM Investigative [1]
Germ cell tumour DC6TMI8 PA1 Investigative [1]
Large cell lung carcinoma DCRR8RL NCI-H460 Investigative [1]
Malignant melanoma DCUABO8 A375 Investigative [1]
Malignant melanoma DCFM6EN RPMI7951 Investigative [1]
Ovarian endometrioid adenocarcinoma DCZZMXP A2780 Investigative [1]
Ovarian serous cystadenocarcinoma DCZOY5B SK-OV-3 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7884).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7943).
4 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
5 Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
6 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.